Alto Neuroscience Inc. Common Stock (ANRO)
Stock · NYSE · Health Care
$21.97as of 10/16/2026
Price chart
Active signals
ANRO Signal Track Record
How signals performed across all stocks →What ANRO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 17 | +0.8% | 53% | September 10, 2026 |
| Bollinger Band Breakout | 14 | -0.5% | 50% | August 13, 2026 |
| Bollinger Band Breakdown | 5 | -3.7% | 40% | September 10, 2026 |
| Any 20-session window (baseline) | +9.2% | 64% |
Computed by MarketWall from daily closing prices since November 15, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ANRO
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat pa…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 68
- Website
- www.altoneuroscience.com/
Fundamentals
- 1-day range
- $21.71$22.63
- Market cap
- $1.11B
- P/E (trailing)
- —
- P/E (forward)
- -6.68
- EPS (trailing)
- $-2.44
- Dividend yield
- —
- Beta
- 1.42
- Avg. volume
- 539.8K
Forecasts
10 analyst ratings
Alto Neuroscience Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ANROAlto Neuroscience Inc. Common Stock$21.94▼ 3.01%Market cap $1.11BP/E —$5.23$37.48
- IVAInventiva S.A. American Depository Shares$2.94▼ 5.47%Market cap $1.10BP/E —$2.57$6.2
- JBIOJade Biosciences Inc. Common Stock$13.47▼ 2.11%Market cap $1.10BP/E —$8.36$28
- LXRXLexicon Pharmaceuticals Inc. Common Stock$1.52▼ 7.88%Market cap $1.05BP/E —$1.1$2.68
- CRVSCorvus Pharmaceuticals Inc. Common Stock$9.52▼ 3.35%Market cap $1.17BP/E —$6.39$26.95
- OLMAOlema Pharmaceuticals Inc. Common Stock$6.58▼ 4.22%Market cap $1.03BP/E —$6.61$36.26
- WVEWave Life Sciences Ltd. Ordinary Shares$3.13▼ 1.88%Market cap $1.19BP/E —$3.56$21.73
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ANRO Alto Neuroscience Inc. Common Stock | $1.11B | — | $21.94 | ▼ 3.01% | $5.23$37.48 |
| IVA Inventiva S.A. American Depository Shares | $1.10B | — | $2.94 | ▼ 5.47% | $2.57$6.2 |
| JBIO Jade Biosciences Inc. Common Stock | $1.10B | — | $13.47 | ▼ 2.11% | $8.36$28 |
| LXRX Lexicon Pharmaceuticals Inc. Common Stock | $1.05B | — | $1.52 | ▼ 7.88% | $1.1$2.68 |
| CRVS Corvus Pharmaceuticals Inc. Common Stock | $1.17B | — | $9.52 | ▼ 3.35% | $6.39$26.95 |
| OLMA Olema Pharmaceuticals Inc. Common Stock | $1.03B | — | $6.58 | ▼ 4.22% | $6.61$36.26 |
| WVE Wave Life Sciences Ltd. Ordinary Shares | $1.19B | — | $3.13 | ▼ 1.88% | $3.56$21.73 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Nicholas Conrad Smith · October 2, 2026 · Option Exercise55.0K @ $2.32
- Nicholas Conrad Smith · September 30, 2026 · Option Exercise24.1K @ $2.35
- Nicholas Conrad Smith · September 30, 2026 · Sale886 @ $26.87
- Nicholas Conrad Smith · September 30, 2026 · Sale23.2K @ $25.78
- Nicholas Conrad Smith · September 29, 2026 · Option Exercise54.4K @ $2.35
- Nicholas Conrad Smith · September 29, 2026 · Option Exercise56.5K @ $2.35
- Nicholas Conrad Smith · September 29, 2026 · Sale110.8K @ $26.58
- Andrew Craig Miller · May 27, 2026 · Grant26.0K
- Amit Etkin · May 14, 2026 · Gift400.0K
- Sanchez Ramiro · May 12, 2026 · Grant11.0K
- Dreyfus Andrew · May 12, 2026 · Grant11.0K
- Cox Christopher Nixon · May 12, 2026 · Grant11.0K
- Manji Husseini · May 12, 2026 · Grant11.0K
- York Gwill · May 12, 2026 · Grant11.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 27.13M
- Total value held
- $599.59M
- Institutional holders
- 108
- Unknown3.71M
- Unknown2.72M
- Unknown2.06M
- Unknown2.01M
- Unknown1.33M
- Unknown1.21M
- Unknown1.10M
- Unknown1.04M
- Unknown912.0K
- Unknown822.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
ANRO mentioned in review of lagging medical stocks
A Yahoo article reviewing medical sector performance noted that many medical stocks have lagged behind Cardinal Health this year. Alto Neuroscience, as a medical‑focused company, is part of that broader discussion. The stock is currently near the lower end of its 52‑week range, which aligns with the sector’s weaker momentum.
ANRO mentioned in review of lagging medical stocks. A Yahoo article reviewing medical sector performance noted that many medical stocks have lagged behind Cardinal Health this year. Alto Neuroscience, as a medical‑focused company, is part of that broader discussion. The stock is currently near the lower end of its 52‑week range, which aligns with the sector’s weaker momentum.